26
|
Koh J, Stehli J, Martin C, Quine E, Dagan M, Dawson L, Dong M, Crawford C, Htun N, Stub D, Walton A, Duffy S. Impact of Left Ventricular Ejection Fraction on Outcomes Following Transcatheter Aortic Valve Implantation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Stehli J, Koh S, Duffy S, Dagan M, Quine E, Dick R, Htun N, Stub D, Marty C, Walton A. Long-term Survival and Valve Durability in Patients Undergoing Transcatheter Aortic Valve Implantation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Koh J, Stehli J, Martin C, Dagan M, Choo C, Crawford C, Dong M, Htun N, Stub D, Walton A, Duffy S. Impact of Gender on Transcatheter Aortic Valve Implantation Outcomes. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Rushton C, Anderson V, Walton A. Assess the benefits of Implementing regular nutritional screening for patients with a lung cancer diagnosis. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30163-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Sinhal A, Hooper T, Ng M, Griffith L, Deakin A, Bhindi R, Brieger D, Muller D, Walton A, Camuglia A, Gooley R, Yong G, Wilson W, Stewart J, Whitbourn R, Isaac M, Walters D, Bennetts J. Is STS Score Enough to Predict Appropriate High-risk Surgical Patient for TAVI. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Hooper T, Ng M, Thomas G, Bennetts J, Bhindi R, Brieger D, Muller D, Walton A, Camuglia A, Gooley R, Whitbourn R, Yong G, Wilson W, Stewart J, Isaac M, Walters D, Sinhal A. Impact of Transcatheter Aortic Valve Implantation on Symptoms and Quality of Life in Australian Patients: Insights from the ACOR TAVI Registry. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Koh J, Stehli J, Martin C, Quine E, Dagan M, Dawson L, Htun N, Stub D, Walton A, Duffy S. Predictors of Clinical Outcomes Following Transcatheter Aortic Valve Implantation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Koh J, Stehli J, Martin C, Dagan M, Dawson L, Liew S, Htun N, Stub D, Walton A, Duffy S. Ten-year Trends in Transcatheter Aortic Valve Implantation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Zhou J, Liew D, Duffy S, Walton A, Htun N, Stub D. Cost-Effectiveness of Transcatheter Aortic Valve Implantation Compared to Surgical Aortic Valve Replacement in the Intermediate Surgical Risk Population. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Hooper T, Bennetts J, Ng M, Griffith L, Deakin A, Bhindi R, Brieger D, Muller D, Walton A, Camuglia A, Gooley R, Whitbourn R, Yong G, Wilson W, Stewart J, Isaac M, Walters D, Sinhal A. Establishment of the Australian Transcatheter Aortic Valve Implantation Registry. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Dagan M, Dawson L, Stehli J, Koh S, Quine E, Walton A, Stub D, Htun N, Duffy S. Incidence, Management and Impact of Incidental Coronary Artery Disease on Outcomes Following Transcatheter Aortic Valve Implantation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A, Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, Forde-McLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol 2018; 3:968-977. [PMID: 30167646 PMCID: PMC6233816 DOI: 10.1001/jamacardio.2018.2936] [Citation(s) in RCA: 117] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Accepted: 08/01/2018] [Indexed: 12/26/2022]
Abstract
Importance In patients with heart failure (HF) and left ventricular ejection fraction (LVEF) equal to or greater than 40%, a transcatheter interatrial shunt device (IASD; Corvia Medical) reduces exercise pulmonary capillary wedge pressure (PCWP) and is safe compared with sham control treatment at 1 month of follow-up. The longer-term safety and patency of the IASD has not yet been demonstrated in the setting of a randomized clinical trial (RCT). Objective To evaluate the 1-year safety and clinical outcomes of the IASD compared with a sham control treatment. Design, Setting, and Participants This phase 2, double-blind, 1-to-1 sham-controlled multicenter RCT of IASD implantation vs a sham procedure (femoral venous access and imaging of the interatrial septum without IASD) was conducted in 22 centers in the United States, Europe, and Australia on patients with New York Heart Association (NYHA) class III or ambulatory class IV HF, LVEF equal to or greater than 40%, exercise PCWP equal to or greater than 25 mm Hg, and PCWP-right atrial pressure gradient equal to or greater than 5 mm Hg. Main Outcomes and Measures Safety was assessed by major adverse cardiac, cerebrovascular, or renal events (MACCRE). Exploratory outcomes evaluated at 1 year were hospitalizations for HF, NYHA class, quality of life, a 6-minute walk test, and device patency. Results After 1 year, shunts were patent in all IASD-treated patients; MACCRE did not differ significantly in the IASD arm (2 of 21 [9.5%]) vs the control arm (5 of 22 [22.7%]; P = .41), and no strokes occurred. The yearly rate of hospitalizations for HF was 0.22 in the IASD arm and 0.63 in the control arm (P = .06). Median improvement in NYHA class was 1 class in the IASD arm (IQR, -1 to 0) vs 0 in the control arm (IQR, -1 to 0; P = .08). Quality of life and 6-minute walk test distance were similar in both groups. At 6 months, there was an increase in right ventricular size in the IASD arm (mean [SD], 7.9 [8.0] mL/m2) vs the control arm (-1.8 [9.6] mL/m2; P = .002), consistent with left-to-right shunting through the device; no further increase occurred in the IASD arm at 12 months. Conclusions and Relevance The REDUCE LAP-HF I phase 2, sham-controlled RCT confirms the longer-term patency of the IASD. Through 1 year of follow-up, IASD treatment appears safe, with no significant differences in MACCRE in patients receiving IASD compared with those who received sham control treatment. Trial Registration ClinicalTrials.gov identifier: NCT02600234.
Collapse
|
38
|
Stehli J, Gupta V, Rashid H, Be K, Martin C, Gooley R, Dick R, Htun N, Stub D, Duffy S, Walton A. Long-Term Outcomes of Patients Undergoing TAVI in Australia. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Mundisugih J, Walton A, Duffy S, Stub D, Johnston R, Holland S, Kaye D, Nanayakkara S. Abnormal Diastology Predicts Long-Term Functional Outcome and Rehospitalisation in Patients Undergoing Transcatheter Aortic Valve Implantation. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Zamani J, Young C, Paratz E, Duffy S, Stub D, Walton A. Clinical Outcome of Transcatheter Aortic Valve Implantation in Nonagenarians: Does Age Really Matter? Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Quine E, Duffy S, Walton A, Dick R, Htun N, Stehli J, Stub D. Comparison of Early Outcomes in Low-, Intermediate- and High-Risk Transcatheter Aortic Valve Implantation Patients. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390:2160-2170. [PMID: 28859944 DOI: 10.1016/s0140-6736(17)32281-x] [Citation(s) in RCA: 501] [Impact Index Per Article: 71.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 08/10/2017] [Accepted: 08/14/2017] [Indexed: 01/12/2023]
Abstract
BACKGROUND Previous randomised renal denervation studies did not show consistent efficacy in reducing blood pressure. The objective of our study was to evaluate the effect of renal denervation on blood pressure in the absence of antihypertensive medications. METHODS SPYRAL HTN-OFF MED was a multicentre, international, single-blind, randomised, sham-controlled, proof-of-concept trial. Patients were enrolled at 21 centres in the USA, Europe, Japan, and Australia. Eligible patients were drug-naive or discontinued their antihypertensive medications. Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater and less than 180 mm Hg, office diastolic blood pressure (DBP) of 90 mm Hg or greater, and a mean 24-h ambulatory SBP of 140 mm Hg or greater and less than 170 mm Hg at second screening underwent renal angiography and were randomly assigned to renal denervation or sham control. Patients, caregivers, and those assessing blood pressure were blinded to randomisation assignments. The primary endpoint, change in 24-h blood pressure at 3 months, was compared between groups. Drug surveillance was done to ensure patient compliance with absence of antihypertensive medication. The primary analysis was done in the intention-to-treat population. Safety events were assessed at 3 months. This study is registered with ClinicalTrials.gov, number NCT02439749. FINDINGS Between June 25, 2015, and Jan 30, 2017, 353 patients were screened. 80 patients were randomly assigned to renal denervation (n=38) or sham control (n=42) and followed up for 3 months. Office and 24-h ambulatory blood pressure decreased significantly from baseline to 3 months in the renal denervation group: 24-h SBP -5·5 mm Hg (95% CI -9·1 to -2·0; p=0·0031), 24-h DBP -4·8 mm Hg (-7·0 to -2·6; p<0·0001), office SBP -10·0 mm Hg (-15·1 to -4·9; p=0·0004), and office DBP -5·3 mm Hg (-7·8 to -2·7; p=0·0002). No significant changes were seen in the sham-control group: 24-h SBP -0·5 mm Hg (95% CI -3·9 to 2·9; p=0·7644), 24-h DBP -0·4 mm Hg (-2·2 to 1·4; p=0·6448), office SBP -2·3 mm Hg (-6·1 to 1·6; p=0·2381), and office DBP -0·3 mm Hg (-2·9 to 2·2; p=0·8052). The mean difference between the groups favoured renal denervation for 3-month change in both office and 24-h blood pressure from baseline: 24-h SBP -5·0 mm Hg (95% CI -9·9 to -0·2; p=0·0414), 24-h DBP -4·4 mm Hg (-7·2 to -1·6; p=0·0024), office SBP -7·7 mm Hg (-14·0 to -1·5; p=0·0155), and office DBP -4·9 mm Hg (-8·5 to -1·4; p=0·0077). Baseline-adjusted analyses showed similar findings. There were no major adverse events in either group. INTERPRETATION Results from SPYRAL HTN-OFF MED provide biological proof of principle for the blood-pressure-lowering efficacy of renal denervation. FUNDING Medtronic.
Collapse
|
43
|
Lixandru A, Venkatesan P, Jönsson C, Poenaru I, Hall B, Yang Y, Walton A, Güth K, Gauß R, Gutfleisch O. Identification and recovery of rare-earth permanent magnets from waste electrical and electronic equipment. WASTE MANAGEMENT (NEW YORK, N.Y.) 2017; 68:482-489. [PMID: 28751173 DOI: 10.1016/j.wasman.2017.07.028] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 05/19/2017] [Accepted: 07/17/2017] [Indexed: 06/07/2023]
Abstract
Nd-Fe-B permanent magnets are a strategic material for a number of emerging technologies. They are a key component in the most energy efficient electric motors and generators, thus, they are vital for energy technologies, industrial applications and automation, and future forms of mobility. Rare earth elements (REEs) such as neodymium, dysprosium and praseodymium are also found in waste electrical and electronic equipment (WEEE) in volumes that grow with the technological evolution, and are marked as critical elements by the European Commission due to their high economic importance combined with significant supply risks. Recycling could be a good approach to compensate for the lack of rare earths (REs) on the market. However, less than 1% of REs are currently being recycled, mainly because of non-existing collection logistics, lack of information about the quantity of RE materials available for recycling and recycling-unfriendly product designs. To improve these lack of information, different waste streams of electrical and electronic equipment from an industrial recycling plant were analyzed in order to localize, identify and collect RE permanent magnets of the Nd-Fe-B type. This particular type of magnets were mainly found in hard disk drives (HDDs) from laptops and desktop computers, as well as in loudspeakers from compact products such as flat screen TVs, PC screens, and laptops. Since HDDs have been investigated thoroughly by many authors, this study focusses on other potential Nd-Fe-B resources in electronic waste. The study includes a systematic survey of the chemical composition of the Nd-Fe-B magnets found in the selected waste streams, which illustrates the evolution of the Nd-Fe-B alloys over the years. The study also provides an overview over the types of magnets integrated in different waste electric and electronic equipment.
Collapse
|
44
|
Noaman S, Vogrin S, Goh C, Cheng Y, Brennan A, Andrianopoulos N, Dinh D, Lefkovits J, Reid C, Walton A, Stub D, Cox N, Chan W. P5583Comparison of short-term clinical outcomes of proximal versus non-proximal culprit lesion in patients treated with primary percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Biswas S, Duffy S, Lefkovits J, Andrianopoulos N, Brennan A, Walton A, Shaw J, Chan W, Ajani A, Clark D, Freeman M, Hiew C, Oqueli Flores E, Reid C, Stub D. P5606Evolving trends in procedural characteristics and clinical outcomes in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Dawson L, Dagan M, Walton A, Stub D, Duffy S, Shaw J. Significance of Iliac Vessel Disease and Coronary Artery Disease in Patients with Severe Aortic Stenosis being Considered for Transcatheter Aortic Valve Implantation. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Biswas S, Duffy S, Lefkovits J, Andrianopoulos N, Brennan A, Walton A, Shaw J, Chan W, Ajani A, Clark D, Freeman M, Hiew C, Oqueli E, Reid C, Stub D. Impact of Socioeconomic Status on Risk Factors, Treatment and Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) for ST-Elevation Myocardial Infarction (STEMI). Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Noaman S, Andrianopoulos N, Brennan A, Reid C, Stub D, Biswas S, Walton A, Clark D, Ajani A, Freeman M, Sebastian M, Duffy S, Chan W. Clinical Outcomes of Cardiogenic Shock Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Bissessor N, Duffy S, Walton A. A Comparative Analysis of Low Risk TAVI Patients with Intermediate/High Risk with Outcomes at Two Years. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
50
|
Biswas S, Seman M, Cox N, Neil C, Brennan A, Dinh D, Walton A, Chan W, Lefkovits J, Reid C, Stub D. The Impact of Doctor-Patient Language Discordance on Presentation and Outcomes of Patients Undergoing Primary PCI for STEMI. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.692] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|